Phase 1a Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of
VGA039 following single IV or SC dose administration in healthy subjects and single SC dose
administration in subjects with Von Willebrand disease.